High Blood Pressure Cure: A Daily Pill May End a Lifetime of Treatment

High blood pressure is the most boring diagnosis in medicine, and also one of the deadliest. More than a billion people live with it, most of them on pills they will take for the rest of their lives. The pills work — they keep the numbers down — but they never finish the job. Stop taking them, and the pressure comes back, because the cause is still there, quietly doing its work.

A study published this week in the New England Journal of Medicine suggests that, for a meaningful slice of those patients, the job might actually be finishable.

The cause in question is primary aldosteronism, a condition in which small benign nodules in the adrenal glands produce too much of the hormone aldosterone. Aldosterone tells the kidneys to hold on to salt, salt holds on to water, and blood pressure climbs. It accounts for somewhere between 5 and 10 percent of all hypertension — around 800,000 cases in Britain alone — and until now the only cure has been surgery: removing an entire adrenal gland. Everything else is management.

The new study, led by Morris Brown at Queen Mary University of London, followed 14 patients at eight centres in the United States who took a drug called baxdrostat once a day for six to twelve months. Baxdrostat blocks aldosterone synthase, the enzyme that makes aldosterone. The idea traces back to a mouse experiment in 2005, which showed that deleting the gene for that enzyme caused the aldosterone-producing cells themselves to disappear. Brown's team predicted that a long enough course of the drug might do the same thing in people — not suppress the hormone while the drug is taken, but remove the cells that make it.

Two years after the patients stopped taking the pills, the results were still there. The main marker of excess aldosterone production was 99 percent lower than before treatment. Blood pressure was, on average, 25 points lower. Almost a quarter of the participants had normal blood pressure without taking any other medication at all.

I want to be careful here, because the study itself is careful. Fourteen patients is a small number, and there was no control group — this was a follow-up of routine measurements, not a randomised trial. Brown himself calls the findings preliminary and says the team is duly cautious. The drug is unlikely to be the elixir for most patients with hypertension, in his words. A larger prospective trial, called ELIXIR, is now being set up, with full results expected in late 2028.

But there are two reasons to take this seriously rather than file it as another promising mouse-to-human story. The first is that the drug class is no longer theoretical. Baxdrostat, sold as Baxfendy by AstraZeneca, was approved by the US Food and Drug Administration in May this year as the first aldosterone synthase inhibitor on the market — a new mechanism of action for blood pressure, the first in more than twenty years. In its Phase III trial it lowered systolic pressure by 15.7 mmHg, about 9.8 mmHg more than placebo. The second reason is that a rival drug in the same class, lorundrostat from Mineralys Therapeutics, has already passed its own Phase III trial and is awaiting an FDA decision, expected by 22 December. The machinery of approval is moving; the question is no longer whether these drugs work, but what exactly they can do.

That is the shift that matters. For decades, hypertension treatment has been built on a single assumption: the patient will take the drug forever. Every guideline, every prescription, every conversation about adherence starts from there. If a finite course of pills — six to twelve months — can switch off the hormone at its source and leave blood pressure normal two years later, then for the millions whose hypertension is driven by aldosteronism, the condition stops being a life sentence and becomes something with an ending. Not for everyone, and not yet proven. But the first evidence that a pill can cure rather than manage high blood pressure is now in the literature, and the larger trial that will test it is already being assembled. I will be watching what it finds — and, sooner than that, what the FDA decides about lorundrostat in December.